

STROBE CHECKLIST

Source of STROBE checklist: https://www.strobe-statement.org/fileadmin/Strobe/uploads/checklists/STROBE_checklist_v4_cohort.pdf

Manuscript title:

SARS-CoV-2 outbreak in a Canadian suburban tertiary hospital necessitating full facility closure: a descriptive observational study

Section	Description	Location in Manuscript
Title and Abstract	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title indicates study type Abstract provides details of outbreak and interventions.
Introduction		
Background and rationale	Explain the scientific background and rationale for the investigation being reported	Introduction
Objectives	State specific objectives, including any prespecified hypotheses	Last paragraph of introduction.
Methods		
Study design	Present key elements of study design early in the paper	Outlined in Methods section (definitions, pandemic preparedness measures, infection control procedures and contact tracing, epidemiologic investigation, etc.) Interventions outlined in Table 1.
Setting	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	First paragraph of methods
Participants	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Definitions of methods and contact tracing details.

Variables	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Outlined in definitions and paragraphs of methods section.
Data sources	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Data representation paragraph of methods
Bias	Describe any efforts to address potential sources of bias	Not applicable. There are limitations outlined in the discussion.
Study size	Explain how the study size was arrived at	As this was a retrospective outbreak review, not applicable. However, sample sizes and details of contact tracing and how cases were defined is provided in Methods.
Quantitative analysis	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Transmission network description in Data Representation. Otherwise all quantitative analysis is proportions.
Statistical methods	Describe all statistical methods	Beyond proportions and transmission network, further statistics were not used.
Results		
Participants	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	Table 2 First paragraph of results section (Outbreak case descriptions) highlights participants.
Descriptive data	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate	Table 2 provides case details. Also Supplementary Table S1. Descriptive data is provided in ‘Chronology of Outbreak’ section of Results.

	number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	
Outcome data	Report numbers of outcome events or summary measures over time	Table 2, Tables S2, S3, and S4 Also: ‘Outbreak Case Descriptions’, ‘Staff Prevalence Screening’, and ‘Transmission Patterns’ sections.
Main results	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Not applicable. See outcome data. Figure 1 displays cases over time. Prevalence screening results in supplementary tables plus ‘Prevalence Screening’ and ‘Transmission Patterns’ sections.
Other analyses	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Figure S1 – transmission network. Cluster evaluation – Table S4. ‘Transmission Patterns’ section of results.
Discussion/Interpretation		
Key results	Summarise key results with reference to study objectives	First paragraph of Interpretation
Limitations	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Limitations section of Interpretation
Interpretation	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from	Paragraphs 2-5 of discussion

	similar studies, and other relevant evidence	
Generalisability	Discuss the generalisability (external validity) of the study results	Paragraphs 2-5 of discussion
Other		
Funding	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Outlined in declarations section.